Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128759 | 0.79 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2B | |
| SCHEMBL20325449 | 0.79 | TP53 (0.46) | SLC6A2SLC6A4SLC6A3FFAR1ACACB | |
| SCHEMBL20233788 | 0.78 | FFAR1 (0.40) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2B | |
| SCHEMBL29343552 | 0.76 | LNPEP (0.37) | FFAR1LNPEP | |
| SCHEMBL21208066 | 0.76 | FFAR1 (0.41) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2B | |
| SCHEMBL23651501 | 0.72 | ACACB (0.32) | ACACB | |
| SCHEMBL20233795 | 0.71 | ACACB (0.32) | SLC6A2SLC6A4FFAR1ACACB | |
| SCHEMBL21341622 | 0.68 | ACACB (0.41) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2B | |
| SCHEMBL20234603 | 0.65 | LNPEP (0.36) | FFAR1LNPEPACACB | |
| SCHEMBL24021874 | 0.64 | ALDH1A1 (0.47) | TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | SLC6A2 4502/4885SLC6A4 4520/4885SLC6A3 4330/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | SLC6A2 4502/4885SLC6A4 4520/4885SLC6A3 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.